Development of a tracheoesophageal fistula (TEF) is a serious complication of treatment for esophageal or lung cancer, especially following radiation therapy. However, development of a TEF as a complication of chemotherapy or tracheal stenting after surgical debulking is quite uncommon. We herein report a rare case involving a patient with advanced adenocarcinoma invading the mediastinum who rapidly developed a TEF after placement of a tracheal stent and administration of nivolumab immunotherapy. A 55-year-old heavy ex-smoker was diagnosed with lung adenocarcinoma with mediastinal invasion. Nine months after first-line therapy (chemotherapy and radiation therapy), he underwent treatment with nivolumab (3 mg/ kg) as fourth-line therapy. Two weeks after the first dose, he underwent mechanical debulking of the tumor with tracheal stenting because of the rapid development of paraesophageal lymph node swelling and severe tracheal stenosis. He received a second dose of nivolumab 2 weeks later; however, imaging studies 12 days after this second dose revealed a huge fistula 
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What Is It about?
We report a rare case involving a patient with advanced lung adenocarcinoma invading the mediastinum who rapidly developed a tracheoesophageal fistula (TEF) after tracheal stent placement and nivolumab immunotherapy. Two weeks after the first dose of immunotherapy, mechanical debulking of the tumor with tracheal stenting was performed because of the rapid severe tracheal stenosis. Two weeks after the second dose, a huge TEF through metastatic lymph node was revealed. Our findings will be of great interest to the readers, especially those involved in the clinical treatment of patients with advanced lung cancer with transmural tracheal invasion treated by immunotherapy.
Introduction
Nivolumab, a monoclonal antibody to the immune-checkpoint protein programmed cell death protein 1, has been approved for the treatment of metastatic non-small cell lung cancer since having conferred a substantial survival benefit in phase III trials [1, 2] . Despite the possibility of an overly vigorous anti-solid tumor response, some reports have stated that only a single dose of nivolumab drastically eradicated the tumor [3, 4] . An acquired tracheoesophageal fistula (TEF) is a life-threatening complication of esophageal or lung cancer. TEF is commonly reported as a complication of radiation therapy and rarely chemotherapy [5] . We herein describe rapid progression of a TEF in a patient with advanced adenocarcinoma invading the mediastinum treated with nivolumab before and after tracheal stent placement.
Case Report
A 55-year-old man presented for evaluation of dyspnea. He was a heavy ex-smoker (Brinkman index of 1,000). An initial imaging study revealed a lung tumor involving the mediastinum, and a biopsy revealed lung adenocarcinoma with an epidermal growth factor receptor wild-type and anaplastic lymphoma kinase-negative status (c-T4N0M0 stage 3A). The patient received concurrent chemotherapy (cisplatin and titanium silicate-1) and radiation therapy (60 Gy) to the mediastinum as first-line therapy. He was treated with several lines of cytotoxic agents, including carboplatin, nab-paclitaxel and pemetrexed, as well as additional radiation therapy for right supraclavicular and upper mediastinal lymph node metastasis.
Established Facts
• Pseudo-progression, tumor growth from treatment effect rather than true disease progression, has been described in immunotherapy.
•
The potential of immunotherapy to mediate dramatic and rapid antitumor effects is well known in several malignant diseases.
Novel Insights
• To point out a potential safety concern: such anti-tumor effect occurring in patients with transmural metastasis/invasion of the trachea could have grave consequences. Nine months after the first-line treatment, he received nivolumab (3 mg/kg) as fourthline therapy. Two weeks after his first dose of nivolumab, he was referred for dysphagia and severe dyspnea. Imaging examination showed rapid progression of paraesophageal lymph node swelling and severe stenosis of the main trachea (Fig. 1) . Because his performance status and Hugh-Jones classification had worsened to 3 and IV, respectively, mechanical debulking of the tumor arising from the membranous trachea was performed, and a silicone stent of 18-mm diameter and 50-mm length (TRACHEOBRONXANE TM DUMON ® TD; Novatech SA, La Ciotat, France) was placed using rigid bronchoscopy (Fig. 2a-c) . Two weeks after Computed tomography scans showed rapid tumor progression before treatment (a) and 2 weeks after the first treatment (b), raising the possibility of "pseudo-progression." Fig. 2 . Bronchoscopy images before and after tracheal stenting and after one dose of nivolumab. a The bronchoscopy images showed tracheal stenosis and the tumor invading membranous trachea. b Electrocautery and mechanical debulking of the tumor were performed. c A silicone stent was placed after mechanical debulking of the tumor. After the second dose of nivolumab, the stent was migrated to necrotic tissue (d) and a huge fistula between the upper trachea and upper part of esophagus was revealed (e). f The fistula opening was clearly visible and had expanded 3 weeks after the second dose of nivolumab. stenting, the patient received a second dose of nivolumab. Recurrent aspiration occurred 10 days after this dose, and he was admitted 2 days later. Chest computed tomography and bronchoscopy revealed a huge fistula between the upper trachea and esophagus through a metastatic lymph node, which was 20-30 mm in size ( Fig. 2d, e; Fig. 3 ). The fistula, both the proximal and distal side of the silicone stent (Fig. 2f) , had expanded and was clearly visible after 1 week. Neither an additional stent nor replacement of the stent was considered because of the fistula site expansion and suffocation risk. The patient underwent gastrostomy and antibiotic therapy. However, he died of the primary disease 2 months later.
Discussion
The reported incidence of malignant TEF in patients with lung cancer ranges from 0.16 to 0.30% [6, 7] . In one study, the median survival time from diagnosis was only 6 weeks in the absence of appropriate treatment [6] . TEF is commonly reported as a complication of radiation therapy and rarely chemotherapy [5] , and various anti-angiogenic agents have been found to increase the risk of fistula formation [8] , especially bevacizumab; such agents can cause delayed healing secondary to impaired angiogenesis according to a previous review [9] . TEF formation is rare not only following immunotherapy but also tracheal stenting after tumor debulking of an invasive tracheal tumor.
The patient in the present report experienced rapid eradiation of a large tumor after two treatments with immunotherapy. Although no histological assessment was performed, the progression of the tumor after the first course of immunotherapy that caused dyspnea and tracheal stenosis might have been "pseudo-progression"; i.e., initial tumor growth followed by tumor regression. A previous review paper showed that approximately 4% of patients with solid tumors who received continued anti-programmed death-ligand 1 treatment after RECIST tumor progression obtained an anti-tumor response [10] . Although our patient underwent mechanical debulking of his rapidly progressing tumor followed by tracheal silicone stenting, it might have been more suitable to use a covered self-expandable metal stent without debulking in view of the risk of TEF following rapid tumor necrosis. The tracheal walls that may have been invaded by the tumor had rapidly necrotized, leading to their collapse and subsequent fistula formation. This rare case highlights that such an anti-tumor effect occurring in patients with transmural metastasis/invasion of the trachea could have grave consequences.
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